The clamor over prescription drug pricing often implies that medicines simply cost too much. But many experts say the debate can easily overlook an important point – is a given treatment really worth the price? To help payers, physicians, and consumers answer this question, the National Comprehensive Cancer Network, a non-profit that develops treatment guidelines, has developed a new tool called Evidence Block to assess whether medicines are affordable in the context of overall cancer care. We spoke with Robert Carlson, the NCCN chief executive, about its approach and its hopes for helping patients make important decisions. This is an edited version…
No Comment